B. Riley has initiated Foghorn Therapeutics (NASDAQ:FHTX) at buy citing the company's development of SMARCA2 inhibitors to fight tumors. The investment bank has a $10 price target (~151% upside ...
Months later, here he is, back in the Super Bowl AGAIN. And he had a message using one GIF for all the haters out there who bet against him or made fun of him or whatever. After jokingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback